Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT) ( DrugBank: Zidovudine, Lamivudine, Abacavir )


1 disease
IDDisease name (Link within this page)Number of trials
325Hereditary autoinflammatory syndrome1

325. Hereditary autoinflammatory syndrome


Clinical trials : 7 Drugs : 16 - (DrugBank : 6) / Drug target genes : 2 - Drug target pathways : 35
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04731103
(ClinicalTrials.gov)
February 202214/7/2020Inhibition of Reverse Transcription in Type I Interferon Mediated NeuropathologyInhibition of Reverse Transcription in Type I Interferon Mediated NeuropathologyAicardi-Goutières SyndromeDrug: Abacavir (ABC);Drug: Lamivudine (3TC);Drug: Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)University of EdinburghNHS Lothian;Medical Research CouncilNot yet recruiting3 Months15 YearsAll24Phase 2United Kingdom